Distant metastases of differentiated thyroid cancer: Diagnosis, treatment and outcome

Nuclear Medicine Review

Volumn 10, Issue 2, 2007, Pages 106-109

  Toubert, Marie Elisabeth ^a   Hindie, Elif ^a   Rampin, Lucia ^a   Al Nahhas, Adil ^b   Rubello, Domenico ^c  

^a SAINT LOUIS HOSPITAL   (France)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c Rovigo Hospital   (Italy)

Author keywords

Diagnosis; Differentiated thyroid cancer; Metastates; Treatment

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; IODINE 131; PROTEIN TYROSINE KINASE INHIBITOR; RETINOIC ACID;

ARTIFICIAL EMBOLISM; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; EARLY DIAGNOSIS; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IMAGE ENHANCEMENT; LEUKEMIA; LUNG FIBROSIS; LUNG METASTASIS; METASTASIS; PROGNOSIS; REVIEW; SURVIVAL TIME; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

CARCINOMA; FLUORODEOXYGLUCOSE F18; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; WHOLE BODY IMAGING;

EID: 39449107736     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998, 338: 297-306.
2. Clark JR, Lai P, Hall F, Borglund A, Eski S, Freeman JL. Variables predicting distant metastases in thyroid cancer. Laryngoscope 2005; 115: 661-667.
3. Casara D, Rubello D, Saladini G et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34: 1626-1631.
4. Shaha AR, Shah JP, Loree TR. Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 1997; 174: 474-476.
5. Hoie J, Stenwig AE, Kullmann HR, Lindegaard M. Distant metastases in papillary thyroid cancer. A review of 91 patients. Cancer 1988; 61: 1-6
6. Benbassat CA, Mechlis-Frish S, Hirsch D. Clinico-pathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid carcinoma. World J Surg 2006; 30: 1088-1095.
7. Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA. Distant metastases in differentiated thyroid carcinoma. A multivariate analysis of prognosis variables. J Clin Endocrinol Metab 1988; 67: 501-508.
8. Dinneen SF, Valimaki MJ, Bergstralh EJ, Goellner JR, Gorman CA, Hay ID. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab 1995; 80: 2041-2045.
9. Lin JD, Huang MJ, Juang JH et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999; 9: 1227-1235.
10. Beasley NJ, Walfish PG, Witterick I, Freeman JL. Cause of death in patients with well-differentiated thyroid carcinoma. Laryngoscope 2001; 111: 989-991.
11. Shoup M, Stojadinovic A, Nissan A et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003; 197: 191-197.
12. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005; 63: 87-93.
13. Durante C, Haddy N, Baudin E et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006; 91: 2892-2899.
14. Cooper DS, Doherty GM, Haugen BR et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16: 109-142.
15. Paoini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W; European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
16. Schlumberger M, Tubiana M, De Vathaire F et al. Long term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63: 960-967.
17. Lin JD, Chao TC, Hsueh C. Follicular thyroid carcinomas with lung metastases: a 23-year retrospective study. Endocr J 2004; 51: 219-225.
18. Schlumberger M, Challeton C, de Vathaire F et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996; 37: 598-605.
19. Bernier MO, Leenhardt L, Hoang C et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001; 86: 1568-1573.
20. Brown AP, Greening WP, McCready VR, Shaw HJ, Harmer CL. Radioiodine treatment of metastatic thyroid carcinoma: The Royal Marsden Hospital experience. Br J Radiol 1984; 5: 323-327.
21. Eustatia-Rutten CF, Romijn JA, Guijt MJ et al. Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 3184-3189.
22. Marcocci C, Pacini F, Elisei R et al. Clinical and biological behavior of bone metastases from differentiated thyroid carcinoma. Surgery 1989; 106: 960-966.
23. Niederle B, Roka R, Schemper M, Fritsch A, Weissel M, Ramach W. Surgical treatment of distant metastases in differentiated thyroid cancer: indication and results. Surgery 1986; 100: 1088-1097.
24. Pacini F, Cetani F, Miccoli P et al. Outcome of 309 patients with metastatic thyroid carcinoma treated with radioiodine. World J Surg 1994; 18: 600-604.
25. Petrich T, Widjaja A, Musholt TJ et al. Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 2001; 28: 203-208.
26. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ. Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 2000; 10: 261-268.
27. Proye CA, Dromer DH, Carnaille BM et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992; 16: 640-646.
28. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP, Links TP. Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 2000; 52: 653-659.
29. Zettinig G, Fueger BJ, Passler C et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma - surgery or conventional therapy? Clin Endocrinol (Oxf) 2002; 56: 377-382.
30. 131I-based detection on outcome. Endocr Relat Cancer (in pres).
31. Baloch ZW, LiVolsi VA. Prognostic factors in well-differentiated follicular-derived carcinoma and medullary thyroid carcinoma. Thyroid 2001; 11: 637-445.
32. Albareda M, Puig-Domingo M, Wengrowicz S et al. Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid. Thyroid 1998; 8: 385-391.
33. Akslen LA, Myking AO, Salvesen H, Varhaug JE. Prognostic importance of various clinicopathological features in papillary thyroid carcinoma. Eur J Cancer 1992; 29A: 44-51.
34. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med. 1981; 70: 511-518.
35. Carcangiu ML, Zampi G, Pupi A, Castagnoli A, Rosai J. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985; 55: 805-828.
36. Hindié E, Melliere D, Lange F et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003, 30: 974-981.
37. Samaan NA, Schultz PN, Haynie TP, Ordonez NG. Pulmonary metastases of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 1985; 60: 376-380.
38. Smit JWA, Vielvoye GJ, Goslings BM. Embolization for vertebral metastases of follicular thyroid carcinoma. J Clin Endocrinol Metab 2000; 85: 989-994.
39. de Vathaire F, Schlumberger M, Delisle MJ et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 1997; 75: 734-739.
40. Rubino C, de Vathaire F, Dottorini ME et al. Second primary malignancies in thyroid cancer patients. Br J Cancer 2003; 89: 1638-1644.
41. Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 1998; 39: 1531-1536.
42. Robbins RJ, Wan Q, Grewal RK et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F] fluoro-2-deoxy-d-glucose positron emission tomography. J Clin Endocrinol Metab 2006; 91: 498-505.
43. Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol 2007; 8:148-156.
44. Simon D, Koehrle J, Reiners C et al. Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 1998; 22: 569-574.
45. Grunwald F, Menzel C, Bender H et al. Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 1998; 39: 1903-1906.
46. Koerber C, Schmutzler C, Rendl J et al. Increased I-131 uptake in local recurrence and distant metastases after second treatment with retinoic acid. Clin Nucl Med 1999; 24: 849-851,
47. Schmutzler C, Kohrle J. Retinoic acid redifferentiation therapy for thyroid cancer. Thyroid 2000; 10: 393-406.
48. Toubert ME, Darsin D, Cassinat B et al. Redifferentiation therapy with retinoids for radioiodine negative thyroid cancer patients. Eur J Nucl Med Mol Imaging 2003; 30 (O106): S172.
49. Filetti S, Bidart JM and Arturi F. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999; 141: 443-457.
50. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer - does it hold its promise? Eur J Endocrinol 2003; 148: 395-402.
51. Courbon F, Zerdoud S, Bastie D et al. Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 2006; 16: 1025-1031.
52. Zhang Y, Jia S, Liu Y, Li B, Wang Z, Lu H et al. A clinical study of alltrans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 2007; 28: 251-255.
53. Cras A, Darsin-Bettinger D, Balitrand N et al. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007; 26: 4018-4024.
54. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005; 353: 172-187.
55. Santoro M, Carlomagno F. Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer. Nat Clin Pract Endocrinol Metab 2006; 2: 42-52.